UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Responder analyses and the assessment of a clinically relevant treatment effect

Trials, 2007-10, Vol.8 (1), p.31-31, Article 31

2007

Volltextzugriff (PDF)

Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study

Clinical journal of the American Society of Nephrology, 2006-07, Vol.1 (4), p.761-767

2006

Volltextzugriff (PDF)

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

The New England journal of medicine, 2001-09, Vol.345 (12), p.861-869

2001

Volltextzugriff (PDF)

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

The American statistician, 2005-11, Vol.59 (4), p.301-307

2005

Volltextzugriff (PDF)

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Annals of internal medicine, 2003-12, Vol.139 (11), p.901

2003

Volltextzugriff (PDF)

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Kidney international, 2003-04, Vol.63 (4), p.1499-1507

2003

Volltextzugriff (PDF)

Proportion of treatment effect (PTE) explained by a surrogate marker

Statistics in medicine, 2003-11, Vol.22 (22), p.3449-3459

2003

Volltextzugriff (PDF)

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2004-07, Vol.292 (1), p.55

2004

Volltextzugriff (PDF)

Noninferiority trials

Trials, 2000-07, Vol.1 (1), Article 19

Snapinn, Steven M

2000

Volltextzugriff (PDF)

Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose

Pharmacology, 2011-01, Vol.87 (1-2), p.63-69

2011

Volltextzugriff (PDF)

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Diabetes care, 2006-03, Vol.29 (3), p.595-600

2006

Volltextzugriff (PDF)

Alternatives for Discounting in the Analysis of Noninferiority Trials

Journal of biopharmaceutical statistics, 2004-12, Vol.14 (2), p.263-273

Snapinn, Steven M.

2004

Volltextzugriff (PDF)

Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies

The American journal of cardiology, 2005-12, Vol.96 (11), p.1530-1536

2005

Volltextzugriff (PDF)

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy : The losartan intervention for endpoint (LIFE) reduction in hypertension study

Circulation (New York, N.Y.), 2006-03, Vol.113 (12), p.1588-1596

2006

Volltextzugriff (PDF)

Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: Angiographic results from the PRISM-PLUS Trial (platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms)

Circulation (New York, N.Y.), 1999-10, Vol.100 (15), p.1609-1615

1999

Volltextzugriff (PDF)

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Volltextzugriff (PDF)

Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates

Statistics in biopharmaceutical research, 2023-01, Vol.15 (1), p.69-73

2023

Volltextzugriff (PDF)

The issue of multiplicity in noninferiority studies

Clinical trials (London, England), 2012-12, Vol.9 (6), p.730-735

2012

Volltextzugriff (PDF)

Benefits and safety of tirofiban among acute coronary Syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in patients limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Circulation (New York, N.Y.), 2002-05, Vol.105 (20), p.2361-2366

2002

Volltextzugriff (PDF)

Informative noncompliance in endpoint trials

Current controlled trials in cardiovascular medicine, 2004-07, Vol.5 (1), Article 5

2004

Volltextzugriff (PDF)

Correlation between the TIMI risk score and high-risk angiographic findings in non–ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

The American heart journal, 2005-05, Vol.149 (5), p.846-850

2005

Volltextzugriff (PDF)

Importance of baseline distribution of proteinuria in renal outcomes trials : Lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Journal of the American Society of Nephrology, 2005-06, Vol.16 (6), p.1775-1780

2005

Volltextzugriff (PDF)

Sex-based short- and long-term survival in patients following complicated myocardial infarction

European heart journal, 2006-09, Vol.27 (18), p.2177-2183

2006

Volltextzugriff (PDF)

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

Hypertension (Dallas, Tex. 1979), 2005-04, Vol.45 (4), p.580-585

2005

Volltextzugriff (PDF)

Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: Insights from the PRISM-PLUS study

International journal of cardiology, 2005-04, Vol.100 (1), p.73-78

2005

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Englisch
(92)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(54)
Humans
(45)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Female
(32)
Male
(32)
Aged
(30)
Middle Aged
(28)
Cardiovascular System & Cardiology
(22)
Losartan - Therapeutic Use
(21)
Hypertension - Drug Therapy
(19)
Mathematics
(19)
Antihypertensive Agents - Therapeutic Use
(18)
Atenolol - Therapeutic Use
(18)
Pharmacology. Drug Treatments
(18)
Medicin Och Hälsovetenskap
(17)
Physical Sciences
(17)
Statistics & Probability
(17)
Cardiac & Cardiovascular Systems
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Responder analyses and the assessment of a clinically relevant treatment effect

Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Proportion of treatment effect (PTE) explained by a surrogate marker

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

Noninferiority trials

Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Alternatives for Discounting in the Analysis of Noninferiority Trials

Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy : The losartan intervention for endpoint (LIFE) reduction in hypertension study

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates

The issue of multiplicity in noninferiority studies

Benefits and safety of tirofiban among acute coronary Syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in patients limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Informative noncompliance in endpoint trials

Correlation between the TIMI risk score and high-risk angiographic findings in non–ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Importance of baseline distribution of proteinuria in renal outcomes trials : Lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Sex-based short- and long-term survival in patients following complicated myocardial infarction

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: Insights from the PRISM-PLUS study

Suchergebnisse filtern